With the Volume-based Procurement (VBP)'s implementation in China for most of the key drug products as well as the medical device as the next step, all the overseas' pharma and device companies should have a clear understanding for China's reimbursement policy when discussing the China market access plan.  By working with Angine's experts in the reimbursement filed, Angine could provide you the following solution when you decide to explore the Chinese market potential for your launched products or the clinical stage products in the overseas' markets.

· China Reimbursement Policies Analysis

· Health Insurance Directory Interpretation in China

· The Commercial Insurance's Opportunities

· The Reimbursement Proposal for the Specified Products

· The Product Pricing Proposal based on the Reimbursement Policy